Skip to Main
Investment Banking

Lead Bookrunner on INOVIO Pharmaceuticals' Public Offering of Common Stock

  • Oppenheimer & Co. Inc.
  • December 19, 2024
Oppenheimer & Co. Inc. acted as Lead Bookrunner on INOVIO Pharmaceuticals' $30.0MM Confidentially Marketed Public Offering of Common Stock

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warrants to purchase 10,000,000 shares of its common stock at an exercise price of $3.76 per share of common stock, at a combined public offering price of $3.00 per share of common stock and accompanying warrant. All of the securities in the offering are being sold by INOVIO.

Inovio deal
Inovio deal

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO and assuming no exercise of the accompanying warrants, are expected to be $30 million.

Michael A. Margolis, R.Ph.
Name:

Michael A. Margolis, R.Ph.

Title:

Senior Managing Director, Head of Healthcare Investment Banking

Address

85 Broad Street
23rd Floor
New York, NY 10004Click to open address in a new window on Google Maps

Contact

(212) 667-7622 MichaelA.Margolis@opco.com
Hide Bio
Name: Title:
Hide Bio
Name: Title:
Hide Bio

DISCLOSURES

This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2024 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7454203.1